Sandra Misale, PhD

Primary Academic Title

Assistant Professor of Oncology

Research Summary

The Misale Lab is interested in understanding the basic mechanisms of sensitivity and resistance to targeted therapies in solid tumors driven by specific genetic alterations.

Our effort is translational science in oncology, working in close contact with clinicians and tackling clinically relevant questions in the lab to bring that information back to patients.

We investigate molecular and pharmacological targets in different malignancies including Colorectal Cancer, Non-Small Cell Lung Cancer and Pancreatic Cancer by merging genetics, pharmacology, and basic cell biology approaches. Our main focus is KRAS targeting and the study of mechanisms of primary, adaptive and secondary resistance to KRAS inhibitors in multiple tumors.

PubMed

https://www.ncbi.nlm.nih.gov/myncbi/sandra.misale.1/bibliography/public/

Selected Publications

• Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. PubMed Central PMCID: PMC3927413

• Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. Cancer Discov. 2020 Aug;10(8):1129-1139. PubMed Central PMCID: PMC7416460

• Li BT*, Michelini F*, Misale S*, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov. 2020 May;10(5):674-687. PubMed Central PMCID: PMC7196485. * Co-First, Co-Corresponding Authors

• Yaeger R, Mezzadra R, Sinopoli J, Bian Y, Marasco M, Kaplun E, Gao Y, Zhao H, Paula ADC, Zhu Y, Perez AC, Chadalavada K, Tse E, Chowdhry S, Bowker S, Chang Q, Qeriqi B, Weigelt B, Nanjangud GJ, Berger MF, Der-Torossian H, Anderes K, Socci ND, Shia J, Riely GJ, Murciano-Goroff YR, Li BT, Christensen JG, Reis-Filho JS, Solit DB, de Stanchina E, Lowe SW, Rosen N, Misale S. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer. Cancer Discov. 2023 Jan 9;13(1):41-55. PubMed Central PMCID: PMC9827113

Honors

• Maryland Moonshot Scholar FY24, Maryland Cancer Moonshot (MCM) Research Grant Program at the Johns Hopkins Medical Institutions, 7/1/23
• Marisa Colbacchini Award for Italian best doctorate thesis in oncological sciences, Carlo Erba Foundation, 3/1/15

Memberships

• American Association for Cancer Research (AACR)
• European Society for Medical Oncology (ESMO)